Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

AstraZeneca Doubles Down On Amyloidosis With Neurimmune Alliance

Fuels Ambition To Be Leading Heart Failure Firm

Executive Summary

The UK major is paying $30m upfront and up to an extra $730m for the rights to Neurimmune’s NI006, which is in Phase Ib trials for the treatment of transthyretin amyloid cardiomyopathy.

You may also be interested in...



AstraZeneca Closes Amyloidosis Gap On Alnylam After Eplontersen Win

AstraZeneca is preparing a US filing for hereditary transthyretin-mediated amyloid polyneuropathy for eplontersen, which it hopes will compete with Pfizer and Alnylam's therapies in that rare disease space.

Alnylam Confident It Won’t Stumble On ATTR Trial Like BridgeBio

Alnylam expects success in its Phase III study in amyloid cardiomyopathy- but a competitor’s baffling failure is making analysts jittery.

AstraZeneca Stays Hopeful About Ultomiris Despite Initial Conversion Difficulties

AstraZeneca is touting Ultomiris’ future potential in neurological conditions as it struggles to convert patients from predecessor Soliris in one of its indications. 

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC145674

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel